April 25. 2007 - Siemens Medical Solutions has expanded its molecular imaging research collaboration with The University of Texas M. D. Anderson Cancer Center, with the establishment of a preclinical research center dedicated to the development of new, targeted biomarkers that may help detect cancers earlier, better visualize cancers at the molecular level and provide more effective, tailored therapies.
Researchers from Siemens and M. D. Anderson will work together at the center to develop novel radio-labeled imaging agents that visualize molecular-genetic targets, facilitating the translation of laboratory findings into clinical imaging applications and helping researchers study the effects of new drugs and other cancer treatments. As part of the agreement, researchers at M. D. Anderson will perform preclinical testing of Siemens’ proprietary and licensed compounds, as well as participate in Siemens’ clinical trials. Siemens will have certain rights to license imaging agents developed through the research.
June 16, 2026 
